Enliven Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -51.38M1.49M
Depreciation and Depletion 0.03M0.10M0.10M0.21M0.30M0.32M
Share-based Compensation 0.90M2.23M3.85M3.19M12.91M20.17M
Gains from Investment Securities 0.39M
Cash from Operations -21.88M-37.40M-46.77M-32.08M-61.27M-73.19M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.02M-0.12M-0.15M4.60M-0.42M
Depreciation & Amortization (CF) 0.03M0.10M0.10M0.20M0.30M0.30M
Change in Working Capital
Change in Account Payables 0.75M0.31M0.39M0.41M-2.25M0.81M
Change in Accured Expenses 1.30M1.75M0.39M1.61M7.66M-0.25M
Other Working Capital Changes 1.39M0.47M0.23M1.59M3.70M4.77M
Investing Activities
Capital Expenditures 0.14M0.02M0.01M0.61M0.15M0.04M
Sales of Property, Plant and Equipment 35.00M
Change in Acquisitions & Divestments 47.50M45.94M120.00M313.91M
Cash from Investing Activities -24.06M-16.72M-1.63M-0.61M-148.41M-36.00M
Financing Activities
Other financing activities 2.00M1.72M
Cash from Financing Activities 43.58M96.88M49.10M-1.80M234.29M133.16M
Additional items
Change in Cash -2.36M42.76M0.70M-34.49M24.61M23.98M
Free Cash Flow -22.02M-37.42M-46.78M-32.69M-61.42M-73.24M
Net Cash Flow -2.36M42.76M0.70M-34.49M24.61M23.98M